Comparative Pharmacology
Head-to-head clinical analysis: TRIDIONE versus ZONISAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIDIONE versus ZONISAMIDE.
TRIDIONE vs ZONISAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases seizure threshold by modulating voltage-gated sodium channels and enhancing GABA-ergic inhibition.
Anticonvulsant; blocks voltage-gated sodium channels and T-type calcium channels, reducing neuronal excitability and seizure propagation. Also weakly inhibits carbonic anhydrase.
300-600 mg orally three times daily; titrate to seizure control.
Oral, initial 100 mg daily, may increase by 100 mg every 2 weeks; maintenance 200-400 mg daily in 1-2 divided doses; maximum 600 mg daily.
None Documented
None Documented
16-24 hours (trimethadione); dimethadione (active metabolite) has a half-life of ~6-12 days, leading to drug accumulation.
Clinical Note
moderateZonisamide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Zonisamide."
Clinical Note
moderateZonisamide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Zonisamide."
Clinical Note
moderateZonisamide + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Zonisamide."
Clinical Note
moderateZonisamide + Fluconazole
Terminal half-life approximately 60-70 hours (range 50-80 hours) in adults; at steady state, half-life may be slightly longer. Clinical context: requires 2-3 weeks to achieve steady state.
Renal: ~70% as unchanged drug and metabolites (including dimethadione); biliary/fecal: minimal (<10%).
Renal: approximately 30% unchanged; remainder as glucuronide conjugate and reduced metabolite. Biliary/fecal: minimal (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Zonisamide."